Read on Twitter
Early Data Show Moderna’s #Coronavirus Vaccine Is 94.5% Effective https://www.nytimes.com/2020/11/16/health/Covid-moderna-vaccine.html?smid=tw-share #IDTwitter
This is good news as: 1) Implies Antibody to Spike protein is protective; 2) Multiple ways to do this (beyond mRNA vaccines); 3) Doubles vaccine supply chain in short term; 4) Moderna vaccine requires just -20C storage/transport.
In Moderna’s trial, 95 people contracted the #coronavirus: 5 in vaccine group and 90 in placebo group. Of the 95 cases, 11 were severe cases (hospitalized) — all in the placebo group.
Full press release at: http://buff.ly/3puVGK6 . Grade 3 (severe) events: after the 1st dose included injection site pain (2.7%). After the 2nd dose: fatigue (9.7%), muscle ache (8.9%), joint ache (5.2%), headache (4.5%), pain (4.1%) and redness at the injection site (2.0%).
By the end of 2020, Moderna expects to have ~20 million doses of mRNA-1273 vaccine (2 dose regimen) to ship in the USA. In 2021, Moderna aims to manufacture 500 million to 1 billion doses globally.
Stability is -20C for 6mo; and stable at 4C for up to 30 days.
Stability is -20C for 6mo; and stable at 4C for up to 30 days.
#moderna press release is much more informative and transparent than Pfizer's press release.
Pfizer just reported 90% efficacy on 94 events, but did not give any actual numeric data; no data on severe cases or adverse events.
Pfizer just reported 90% efficacy on 94 events, but did not give any actual numeric data; no data on severe cases or adverse events.
